SCHEMBL26090579

SCHEMBL26090579

CS(=O)(=O)NCC(=O)N(Cc1ccccc1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 7/20 0.51
HDAC1 Q13547 6/20 0.51
HDAC8 Q9BY41 4/20 0.51
KMT2A Q03164 3/20 0.50
LTB4R2 Q9NPC1 2/20 0.50
MEN1 O00255 2/20 0.50
NR3C1 P04150 2/20 0.47
ALDH1A1 P00352 2/20 0.46
NPC1 O15118 1/20 0.46
JAK2 O60674 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
PAX8 Q06710 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.45
HDAC5 Q9UQL6 2/20 0.44
THRB P10828 1/20 0.43
PTPRB P23467 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26091134 0.79 CYP1A2 (0.46) KMT2AMEN1ALDH1A1NPC1JAK2
SCHEMBL26091198 0.79 PTPRB (0.49) KMT2ALTB4R2NR3C1ALDH1A1NPC1
SCHEMBL7342383 0.74 HDAC1 (0.69) HDAC6HDAC1HDAC8KMT2ALTB4R2
SCHEMBL1334800 0.72 HDAC1 (0.49) HDAC6HDAC1HDAC8KMT2ALTB4R2
SCHEMBL5995235 0.71 ALDH1A1 (0.54) KMT2AMEN1ALDH1A1HTT
SCHEMBL10312254 0.70 CYP19A1 (0.57) KMT2AMEN1NR3C1RAB9A
SCHEMBL3058600 0.70 RAB9A (0.51) HDAC6HDAC1HDAC8KMT2ALTB4R2
SCHEMBL11117024 0.69 DCUN1D1 (0.46) HDAC6HDAC1HDAC8KMT2ALTB4R2
SCHEMBL11696683 0.69 TSHR (0.64) KMT2AMEN1NR3C1ALDH1A1KDM4E
SCHEMBL19745672 0.68 MEN1 (0.51) HDAC6HDAC1HDAC8KMT2ALTB4R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230129487-A1 SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS OREGON STATE UNIVERSITY (US) 2023-04-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129487-A1 SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS BCL2, BCL2L1, BCL2L13 HDAC6 1843/4885HDAC1 1970/4885HDAC8 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.